The HIF pathway as a therapeutic target
详细信息 查看全文
- 作者：Hewitson ; Kirsty S. ; Schofield ; Christopher J.
- 关键词：Drug Discovery ; Biochemistry ; Cell biology ; Cancer biology ; Pharmaceutical Science ; Molecular Medicine ; angiogenesis ; cancer ; erythropoeitin ; hydroxylase ; hypoxia-inducible factor ; ischemic disease ; JmjC ; oxoglutarate dependent oxygenase ; post-translation
- 刊名：Drug Discovery Today
- 出版年：2004
- 出版时间：August, 2004
- 年：2004
- 卷：9
- 期：16
- 页码：704-711
- 全文大小：288 K
文摘
Hypoxia-inducible factor (HIF) is an α,β-heterodimeric transcription factor that mediates cellular responses to low oxygen concentration via the transcriptional activation of specific genes involved in both tumorogenesis and angiogenesis. Manipulation of the HIF pathway has potential use for the treatment of ischemic disease and cancer. Unlike HIF-β, which is constitutively expressed, the levels and activity of the HIF-α subunit are regulated by processes involving posttranslational hydroxylation, catalyzed by Fe(II)- and 2-oxoglutarate-dependent oxygenases. This review focuses on the HIF pathway as a therapeutic target.